{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:23:28Z","timestamp":1791357808889,"version":"4.3.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.1001\/jamainternmed.2022.0605","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:01:11Z","timestamp":1649084471000},"page":"592","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients"],"prefix":"10.1001","volume":"182","author":[{"given":"Ajay K.","family":"Singh","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Cizman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carroll","sequence":"additional","affiliation":[{"name":"KJC Statistics, Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Glasgow University, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[{"name":"George Institute for Global Health, New Delhi, India"},{"name":"School of Public Health, Imperial College, London, United Kingdom"},{"name":"Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio T.","family":"Obrador","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Panamericana, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Waikar","sequence":"additional","affiliation":[{"name":"School of Medicine, Boston University, Boston, Massachusetts"},{"name":"Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Stankus","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Strutz","sequence":"additional","affiliation":[{"name":"DKD Helios Klinik Wiesbaden, KfH und Nierenzentrum-Rheumatologie Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Blackorby","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Cobitz","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Meadowcroft","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitanjali","family":"Paul","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Sedani","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"ioi220012r1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2215\/CJN.01170905","article-title":"Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"2","author":"Bradbury","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"ioi220012r2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/ckj\/sfv021","article-title":"The first year on haemodialysis: a critical transition.","volume":"8","author":"Broers","year":"2015","journal-title":"Clin Kidney J"},{"issue":"8","key":"ioi220012r3","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1093\/ndt\/gfq073","article-title":"Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.","volume":"25","author":"Fort","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"ioi220012r4","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1681\/ASN.V7102169","article-title":"Early death in dialysis patients: risk factors and impact on incidence and mortality rates.","volume":"7","author":"Soucie","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ioi220012r5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ki.2012.133","article-title":"Starting dialysis is dangerous: how do we balance the risk?","volume":"82","author":"McIntyre","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"ioi220012r6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/MNH.0000000000000554","article-title":"Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.","volume":"28","author":"McMahon","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"ioi220012r7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy.","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"ioi220012r8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease.","volume":"365","author":"Semenza","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"ioi220012r9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/13543784.2018.1493455","article-title":"Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.","volume":"27","author":"Del Vecchio","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"ioi220012r10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020389","article-title":"Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease.","volume":"19","author":"Kaplan","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ioi220012r11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.1997.77","article-title":"Structural and functional analysis of hypoxia-inducible factor 1.","volume":"51","author":"Semenza","year":"1997","journal-title":"Kidney Int"},{"issue":"8","key":"ioi220012r12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial.","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"ioi220012r13","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia.","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ioi220012r14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"issue":"25","key":"ioi220012r15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis.","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"ioi220012r16","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis.","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"ioi220012r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"ioi220012r18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab318","article-title":"The ASCEND-ND trial: study design and participant characteristics.","author":"Perkovic","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"ioi220012r19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab065","article-title":"Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.","author":"Singh","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"ioi220012r22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/tap.2014.18.issue-5","article-title":"Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.","volume":"18","author":"Akizawa","year":"2014","journal-title":"Ther Apher Dial"},{"issue":"1","key":"ioi220012r23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2019.01.017","article-title":"Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference.","volume":"96","author":"Chan","year":"2019","journal-title":"Kidney Int"},{"issue":"8","key":"ioi220012r24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2011060597","article-title":"The Achilles heel of mortality risk by dialysis modality is selection bias.","volume":"22","author":"Jaar","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ioi220012r25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients.","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"ioi220012r26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis.","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi220012r27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ekir.2020.12.018","article-title":"Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis.","volume":"6","author":"Provenzano","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"ioi220012r28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1053\/j.ajkd.2021.06.019","article-title":"Hypoxia-inducible factor stabilization as an emerging therapy for CKD-related anemia: report from a scientific workshop sponsored by the National Kidney Foundation.","volume":"78","author":"Wish","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ioi220012r21","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"ioi220012r20","unstructured":"International Council for Harmonisation. E1: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. 1994. Accessed December 16, 2021. https:\/\/www.ich.org\/page\/efficacy-guidelines"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2790862\/jamainternal_singh_2022_oi_220012_1654268169.48535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:09:40Z","timestamp":1654528180000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2790862"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.0605","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}